Clin2
NCT04924270Possibly a fitRecruiting

Capsule stool transfer for newly diagnosed inflammatory bowel or joint disease

Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisCrohn DiseaseUlcerative Colitis

Part of Bones, joints & muscles, Digestive system, Immune system & allergy, Skin clinical trials.

This Phase 2 study tests whether taking capsule stool (FMT) is safe and can help people who are newly diagnosed and haven’t started the usual medicines yet. Participants will also start the standard first-line treatment for their condition, and the study will compare safety and outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You’re 18 to 75 years old
  • You have a newly diagnosed chronic inflammatory disease: RA, AS, PsA, PSar, Crohn’s disease, or ulcerative colitis
  • You have not started key arthritis/immune medicines in the last 3 months (and have not used stronger anti-inflammatory steroid treatment)
  • You plan to start the usual first treatment your national guideline recommends after the baseline visit
  • You do not need “biologic” medicines as the first treatment (your condition is not primarily treated that way)
  • You do not have reasons to avoid FMT (for example: celiac disease/serious food allergy, current cancer, certain infections like HIV or active TB)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07639177Not yet recruiting· Phase 2
Fecal Microbiota Transplant for Hard-to-Treat Rheumatoid Arthritis

This trial tests whether transferring healthy gut bacteria from a donor to patients with rheumatoid arthritis that hasn't improved on standard medications can reduce joint pain and swelling. The goal is to see if rebalancing the gut microbiome (the community of bacteria in your intestines) helps control inflammation.

Beijing, Beijing Municipality
NCT04970446Recruiting· Phase 1/Phase 2
Fecal transplant to restore gut microbes in Crohn’s

This Phase 1/2 study tests whether a fecal microbiome transplant (FMT) can reduce active inflammation in people with Crohn’s disease. It’s designed for people who currently have signs of active bowel inflammation and can attend regular procedure visits.

Melbourne, Victoria
NCT04997733Recruiting· Phase 3
Stool transplant to maintain Crohn’s remission after stopping anti-TNF

This Phase 3 study tests whether transplanting stool bacteria can help people with Crohn’s stay in remission after they stop an anti-TNF medicine. It may help some patients who are currently doing well but need to come off anti-TNF treatment.

Paris
NCT06451588Recruiting· Phase 2
Fecal transplant for inflammatory back pain

This study tests whether a fecal microbiota transplant (a procedure that transfers healthy bacteria into your gut) can reduce inflammation and improve symptoms in people with inflammatory back pain (axial spondyloarthritis). It may help if your current treatments are not working well enough.

Tromsø
NCT07401680Recruiting· Phase 1
Stool transplant for active ulcerative colitis

This trial tests whether a stool transplant (fecal microbiota transplantation) can help manage active ulcerative colitis. You would receive a transplant from a healthy donor to see if it improves your symptoms.

Calgary, Alberta
NCT05327790Recruiting· Phase 2
Fecal transplant to boost new biologic treatment for ulcerative colitis

This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.

Edmonton, Alberta

Hear when a new Rheumatoid arthritis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.